Balanced news tone
News Sentiment
688578 sentiment intelligence
Shanghai Allist Pharmaceuticals Co., Ltd. news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.
Price is moving more forcefully than the current news tone suggests.
72/100 classification confidence.
directly relevant articles
high-authority source matches
-6.7% over one week, +34.9% over four weeks, trend active, and materially above fair value.
Shanghai Allist Pharmaceuticals Hits Day High with 11.09% Surge
Market Reaction
Price moving ahead of tone
Price is moving more forcefully than the current news tone suggests.
Sentiment Mix
Positive, neutral, negative
Relevance
Why the article matched
Sources
Coverage mix
Event Lens
What the news is about
Sentiment Trail
Score over time
News Tape
Relevant headlines
Shanghai Allist Pharmaceuticals Hits Day High with 11.09% Surge
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 21 Jul 2026 16:04
- Source
- MarketsMojo
Shanghai Allist Pharmaceuticals (688578) Q2 2024 earnings summary
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 20 Jul 2026 10:04
- Source
- Quartr
Shanghai Allist Pharmaceuticals (688578) Q1 2026 earnings summary
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 15 Jul 2026 20:17
- Source
- Quartr
Enterprise value to revenue forward of Shanghai Allist Pharmaceuticals Co. Ltd. Class A – SSE:688578
- Tone
- Neutral 50/100
- Event
- Earnings
- Published
- 12 Jul 2026 13:57
- Source
- TradingView
Allist Pharma Urges Caution Following Stock Surge
- Tone
- Positive 66/100
- Event
- Market update
- Published
- 05 Jul 2026 07:00
- Source
- Moomoo
Jacobio Out-licensed KRAS G12C Inhibitor Glecirasib and SHP2 Inhibitor JAB-3312 to Allist in China
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Aug 2024 07:00
- Source
- PR Newswire
Allist pays Jacobio $21M for KRAS drug combo, landing leading role in Chinese cancer race
- Tone
- Neutral 50/100
- Event
- Market update
- Published
- 30 Aug 2024 07:00
- Source
- Fierce Biotech